Post Covid - City Recovery, Progress, Ideas...

[youthathletics]

What is taking place in DC


https://www.bisnow.com/washington-dc/ne ... ubs-123059

Downtown Action Plan: https://www.reimaginedowntowndc.com/
DC Comeback Plan: https://dmped.dc.gov/sites/default/file ... ll1923.pdf

[youthathletics]

In NoVA: https://www.bisnow.com/washington-dc/ne ... nge-123074

[runrussellrun]

sadly, there is nothing further to learn on how we handled, and continue to handle, the pandemic.

https://www.c-span.org/video/?533510-1/ ... ty-systems

so much to learn, so much to censor.

Trumps vaccine.............and those that hate him LOVE his vaccine.

lunacy.

YOUTH.......nothing to learn.

[runrussellrun]

https://rumble.com/v4ggsof-the-highligh ... hey-h.html


Sucks can't find this video, or any videos related to this roundtable on youtube.

Again......NOTHING to learn from how we handled covid.

remember when youtube censored the vaccine injured Documentary, "anectodals" ?

[runrussellrun]

Dr. Miller-Weeks, a US Congressperson, and medical doctor who actually worked in giving covid vaccines.....IS concerned about our Federal programs, and the confusion that victims of vaccine injuries are encountering in attempting to file claims.


https://www.hrsa.gov/cicp

Who Is Eligible to File a Claim for Benefits?
On the rare chance you suffered a serious injury, or the death of a loved one, from the administration or use of a covered countermeasure, you may be eligible to file a claim for benefits.

You must file a Request for Benefits Package within one year of receiving or using the countermeasure that you believe caused the injury. You must also provide proof that a covered countermeasure was administered or used.

Learn more about the criteria for demonstrating that a covered injury occurred.

[runrussellrun]

https://covid.cdc.gov/covid-data-tracke ... ectiveness

Updates on COVID-19 Vaccine Effectiveness
CDC studies published from April 2023–August 2023 on COVID-19 vaccine effectiveness found the following:

Effectiveness in Adults
Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period - IVY Network, 19 U.S. States, February 1, 2022–January 31, 2023 MMWR/ April 28, 2023 / 72(17); 463–468
Original monovalent (ancestral SARS-CoV-2 strain) mRNA vaccination was 76% effective in preventing COVID-19–associated invasive mechanical ventilation and death up to 6 months after the last dose and remained 56% effective at 1–2 years.
Original mRNA COVID-19 vaccines provided substantial, durable protection against COVID-19-associated invasive mechanical ventilation and death. All adults should remain up to date with recommended COVID-19 vaccination to prevent critical outcomes of COVID-19.
Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19–Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022–April 2023 MMWR / May 26, 2023 / 72(21); 579–588
Among adults aged ≥18 years without immunocompromising conditions, bivalent (ancestral and BA.4/BA.5 strains) vaccine effectiveness (VE) against COVID-19–associated hospitalization declined from 62% at 7–59 days postvaccination to 24% at 120–179 days compared with VE among unvaccinated adults. Among immunocompromised adults, lower bivalent booster VE was observed. However, bivalent booster VE was sustained against critical COVID-19-associated outcomes, including intensive care unit admission or death.
Adults should stay up to date with recommended COVID-19 vaccines. Optional additional bivalent vaccine doses are available for older adults and persons with immunocompromising conditions.
Effectiveness of Up-to-Date COVID-19 Vaccination in Preventing SARS-CoV-2 Infection Among Nursing Home Residents - United States, November 20, 2022–January 8, 2023 MMWR / June 23, 2023 / 72(25); 690–693
Among nursing home residents who were up to date with COVID-19 vaccination (most had received a bivalent vaccine), vaccine effectiveness against SARS-CoV-2 infection was 31.2%.
Staying up to date with COVID-19 vaccination recommendations and, if eligible, getting an additional bivalent dose, provides additional protection against SARS-CoV-2 infection. Nursing home residents would benefit from the protection offered by staying up to date with recommended COVID-19 vaccinations.
Effectiveness in Children
Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months–5 Years — VISION Network, United States, July 2022–June 2023
Using data from the VISION network, CDC evaluated the vaccine effectiveness against COVID-19-associated emergency department and urgent care visits by the length of time since the last dose was received during July 4, 2022–May 2023 among children ages 6 months to 4 years (Pfizer-BioNTech) and 6 months to 5 years (Moderna).
Both the original (monovalent) mRNA COVID-19 vaccine series and the bivalent vaccine provide protection against COVID-19-associated emergency department and urgent care visits in children ages 6 months to 4 years (Pfizer-BioNTech) and 6 months to 5 years (Moderna). All children should stay up to date with recommended COVID-19 vaccines, including starting the vaccination series as soon as they’re eligible.
Children continue to be impacted by COVID-19. As of June 2023, there were more than 2 million COVID-19 cases, more than 20,000 hospitalizations, and more than 400 deaths in U.S. children aged 6 months to 4 years. All children aged 6 months and older should stay up to date with recommended COVID-19 vaccines, including starting the vaccine series as soon as they’re eligible and completing it within the recommended time for the best protection. ALL..........had other health issues. prove suck wrong
Read all of CDC's COVID-19 vaccine effectiveness studies that have been published in MMWR: Reports by Topic | MMWR (cdc.gov)

Vaccine Effectiveness (VE) Estimates
The publications in the table are organized by date of publication, with the most recent first. Studies that included more than one outcome or multiple age groups are listed more than once and the table can be sorted by these variables.

Outcome

All outcomes

SARS-CoV-2 infection

Multisystem inflammatory syndrome

Critical illness

Emergency department/urgent care visits

Hospitalization

Invasive mechanical ventilation (IMV) or death
Age Group

All age groups

Adults

Adolescents

Children

Infants
Outcome Vaccine effectiveness* Age Group Vaccine(s)# Population Study period Monitoring System Publication Date/Journal/First author
Emergency department/urgent care visits 23% among children aged 6 months-5 years ≥14 days after 1st dose of original monovalent Moderna, Omicron period
29% among children aged 6 months-5 years ≥14 days after 2nd dose of original monovalent Moderna, Omicron period
Children
Original monovalent mRNA, Moderna 8 states July 4, 2022 – June 17, 2023 VISION 8/18/23 MMWR, Link-Gelles, R
Emergency department/urgent care visits 17% among children aged 6 months-4 years ≥14 days to 1 month after 1st dose of original monovalent Pfizer, Omicron period
37% among children aged 6 months-4 years ≥14 days after 2nd dose of original monovalent Pfizer, Omicron period
43% among children aged 6 months-4 years ≥14 days after 3rd dose of original monovalent Pfizer, Omicron period
Children
Original monovalent mRNA, Pfizer 8 states July 4, 2022 – June 17, 2023 VISION 8/18/23 MMWR, Link-Gelles, R
Emergency department/urgent care visits 80% ≥14 days after ≥1 bivalent dose among children aged 6 months-5 years who received at least a primary series irrespective of manufacturer, Omicron period
Children
Bivalent mRNA 8 states December 24, 2022 – June 17, 2023 VISION 8/18/23 MMWR, Link-Gelles, R
SARS-CoV-2 infection 31.2% among nursing home residents who were up to date with COVID-19 vaccination, Omicron period
Nursing home residents
Bivalent booster, mRNA U.S. skilled nursing facilities Nov. 20, 2022 – Jan. 8, 2023 NHSN 6/23/23 MMWR, Wong, E
Hospitalization 62% during the first 7–59 days after the bivalent dose among immunocompetent adults, Omicron period
24% at 120–179 days after the bivalent dose among immunocompetent adults, Omicron period
28% during the first 7–59 days after the bivalent dose among immunocompromised adults, Omicron period
13% at 120–179 days after the bivalent dose among immunocompromised adults, Omicron period
Adults
Bivalent booster, mRNA 7 states Sept. 13, 2022 –April 21, 2023 VISION 5/26/23 MMWR Link-Gelles, R
Critical illness 69% during the first 7–59 days after the bivalent dose among immunocompetent adults, Omicron period
50% by 120–179 days after the bivalent dose among immunocompetent adults, Omicron period
40% during the first 7–59 days after the bivalent dose among immunocompromised adults, Omicron period
53% at 120–179 days after the bivalent dose among immunocompromised adults, Omicron period
Adults
Bivalent booster, mRNA 7 states Sept. 13, 2022 –April 21, 2023 VISION 5/26/23 MMWR Link-Gelles, R
Invasive mechanical ventilation (IMV) or death 76% <6 months after the last original monovalent dose among immunocompetent adults 56% at ≥1 year after last original monovalent dose among immunocompetent adults
Adults
Original monovalent mRNA 21 U.S. Hospitals Feb. 1, 2022 – Jan. 31, 2023 IVY 4/28/23 MMWR DeCuir, J
SARS-CoV-2 infection 40% among children age 3-5 years 14 days to 1 month after 1st dose of monovalent Moderna, Omicron period
60% among children age 3-5 years 14 days to 2 months after 2nd dose of monovalent Moderna, Omicron period
36% among children age 3-5 years 3 to 4 months after 2nd dose of monovalent Moderna, Omicron period
Children
mRNA, Moderna 49 states, Washington, D.C., and Puerto Rico July 4, 2022–February 5, 2023 ICATT 2/17/23 MMWR, Fleming Dutra K
SARS-CoV-2 infection 19% among children age 3-4 years 14 days to 1 month after 1st dose of monovalent Pfizer, Omicron period
40% among children age 3-4 years 14 days to 3 months after 2nd dose of monovalent Pfizer, Omicron period
31% among children age 3-4 years 14 days to 4 months after 3rd dose of monovalent Pfizer, Omicron period
Children
mRNA, Pfizer 49 states, Washington, D.C., and Puerto Rico July 4, 2022–February 5, 2023 ICATT 2/17/23 MMWR, Fleming Dutra K
SARS-CoV-2 infection 52% relative VE among adults age 18-49 ≥14 days after bivalent booster dose compared with those who received 2-3 monovalent doses only, BA.5-related sublineages
43% relative VE among adults age 50-64 ≥14 days after bivalent booster dose compared with those who received 2-4 monovalent doses only, BA.5-related sublineages
37% relative VE among adults age ≥65 ≥14 days after bivalent booster dose compared with those who received 2-4 monovalent doses only, BA.5-related sublineages
Adults
Bivalent Booster, mRNA 49 states, Washington, D.C., and Puerto Rico December 1, 2022–January 13, 2023 ICATT 2/3/2023 MMWR, Link-Gelles R
SARS-CoV-2 infection 49% relative VE among adults age 18-49 ≥14 days after bivalent booster dose compared with those who received 2-3 monovalent doses only, XBB/XBB.1.5-related sublineages
40% relative VE among adults age 50-64 ≥14 days after bivalent booster dose compared with those who received 2-4 monovalent doses only, XBB/XBB.1.5-related sublineages
43% relative VE among adults age ≥65 ≥14 days after bivalent booster dose compared with those who received 2-4 monovalent doses only, XBB/XBB.1.5-related sublineages
Adults
Bivalent Booster, mRNA 49 states, Washington, D.C., and Puerto Rico December 1, 2022–January 13, 2023 ICATT 2/3/2023 MMWR, Link-Gelles R
Emergency department/urgent care visits 56% ≥7 days after bivalent booster compared with no vaccination, Omicron BA.5 period
34% relative VE ≥7 days after bivalent booster compared with those who received their last monovalent dose 2-4 months earlier
50% relative VE ≥7 days after bivalent booster compared with those who received their last monovalent dose ≥11 months earlier
Adults
Bivalent Booster, mRNA 9 states September 13, 2022–November 18, 2022 VISION 12/16/2022 MMWR, Tenforde M
Hospitalization 59% 7 days after bivalent booster among immunocompetent adults compared with no vaccination
48% relative VE ≥7 days after bivalent booster compared with those who received their last monovalent dose ≥11 months earlier
Adults
Bivalent Booster, mRNA 9 states September 13, 2022–November 18, 2022 VISION 12/16/2022 MMWR, Tenforde M
Hospitalization 84% 7 days after bivalent booster among immunocompetent adults compared with no vaccination, Omicron period
73% relative VE ≥ 7 days after bivalent booster among immunocompetent adults ages >65 compared with monovalent vaccination alone, Omicron period
Adults
Bivalent Booster, mRNA 22 hospitals in 18 states September 8, 2022–November 30, 2022 IVY 12/16/2022 MMWR, Surie D
SARS-CoV-2 infection 56% relative VE among ages 18-49 years compared with those who received their last monovalent dose ≥8 months earlier
48% relative VE among ages 50-64 years compared with those who received their last monovalent dose ≥8 months earlier
43% relative VE among those ages ≥65 years compared with those who received their last monovalent dose ≥8 months earlier
Adults
Bivalent Booster, mRNA 49 states, Washington, D.C., and Puerto Rico September 14, 2022–November 11, 2022 ICATT 11/22/2022 MMWR, Link-Gelles R
Hospitalization 39% ≥14 days after 2nd dose, BA.1/BA.2 period
69% ≥7 days after 3rd dose, BA.1/BA.2 period
61% ≥7 days after 4th dose, BA.1/BA.2 period
41% ≥14 days after 2nd dose, BA.4/BA.5 period
31% ≥7 days after 3rd dose, BA.4/BA.5 period
60% ≥7 days after 4th dose, BA.4/BA.5 period
(median interval between the last dose and illness onset = 145 days)
Adults
mRNA 18 states December 26, 2021–August 31, 2022 IVY 10/21/2022 MMWR, Surie D
Hospitalization 36% ≥ 14 days after 2nd dose among immunocompromised adults, Omicron period
57% ≥7 days after 3rd dose among immunocompromised adults, Omicron period
69% 7-89 days after 3rd dose among immunocompromised adults, Omicron period
44% ≥90 days after 3rd dose among immunocompromised adults, Omicron period
Adults
mRNA 10 states December 16, 2021–August 20, 2022 VISION 10/21/2022 MMWR, Britton A
Hospitalization 61% for 2 doses during BA.1
92% for 3 doses 7–119 days after 3rd dose during BA.1
85% for 3 doses ≥120 days after 3rd dose during BA.1
24% for 2 doses during BA.2/BA.2.12.1
69% for 3 doses 7–119 days after 3rd dose during BA.2/BA.2.12.1
52% for 3 doses ≥120 days after 3rd dose during BA.2/BA.2.12.1
55% for 3 doses among ≥50yo ≥120 days after 3rd dose during BA.2/BA.2.12.1
80% for 4 doses among ≥50yo >1 week after 4th dose during BA.2/BA.2.12.1
Adults
mRNA 10 states Dec 18, 2021–Jun 10, 2022 VISION 7/22/2022 MMWR, Link-Gelles R
SARS-CoV-2 infection 58% overall, without prior infection
67% ≤150 days of receipt of the 2nd dose of Pfizer-BioNTech, pre-Delta period
75% ≤150 days of receipt of the 2nd dose of Moderna, pre-Delta period
33% >150 days of receipt of the 2nd dose of Pfizer-BioNTech, Delta period
77% >150 days of receipt of the 2nd dose of Moderna, Delta period
Adults
mRNA 4,315 residents in 105 nursing homes in 10 states Dec 14, 2020–Nov 9, 2021 N/A 7/20/2022 CID, Hatfield KM
Hospitalization 52% overall
70% against ICU admission
47% against non-ICU hospitalization
80% during Delta
38% during Omicron
69% for either variant when maternal vaccination occurred after 20 weeks of pregnancy
38% when maternal vaccination occurred during the first 20 weeks of pregnancy
Infants (<6 months)
mRNA (maternal vaccination) 30 pediatric hospitals across 22 states Jul 1, 2021–Mar 8, 2022 Overcoming Covid-19 6/22/2022 NEJM, Halasa NB
SARS-CoV-2 infection 17.8% 14 days to 1 month since one dose of Janssen
8.4% 2 to 4 months since one dose of Janssen
27.9% two doses of Janssen, 14 days to 1 month since last dose
29.2% two doses of Janssen, 2 to 4 months since last dose of Janssen
61.3% Janssen/mRNA booster, 14 days to 1 month since last dose
45.3% Janssen/mRNA booster, 2 to 4 months since last dose
68.9% 3 mRNA doses, 14 days to 1 month since last dose
62.8% 3 mRNA doses, 2 to 4 months since last dose
Adults
Janssen, mRNA 49 states, Washington, D.C., and Puerto Rico Jan 2–Mar 23, 2022 (Omicron) ICATT 5/25/2022 NEJM, Accorsi EK
SARS-CoV-2 infection 60.1% among children during month 0 after the second dose
28.9% during month 2 after the second dose
59.5% among adolescents during month 0 after the second dose
16.6% during month 2 after the second dose
71.1% among adolescents 2 to 6.5 weeks after third dose
Children (5–11 years)
Adolescents (12–15 years)
mRNA 49 states, Washington, D.C., and Puerto Rico Dec 26, 2021–Feb 21, 2022 (Omicron) ICATT 5/13/2022 JAMA, Fleming-Dutra KE
SARS-CoV-2 infection 46.9% (relative VE compared to primary series only) after additional or booster dose
Nursing home residents
mRNA U.S. skilled nursing facilities Feb 14–Mar 27, 2022 (Omicron) NHSN 5/6/2022 MMWR, Prasad N
Hospitalization 68% in children after 2 doses, median interval since vaccination 34 days (Omicron†)
93% in adolescents after 2 doses, 2 to 22 weeks after vaccination (Delta†)
92% in adolescents after 2 doses, 23 to 44 weeks after vaccination (Delta†)
43% in adolescents after 2 doses, 2 to 22 weeks after vaccination (Omicron†)
38% in adolescents after 2 doses, 23 to 44 weeks after full vaccination (Omicron†)
Children (5–11 years)
Adolescents (12–18 years)
mRNA 23 states Jul 1, 2021–Feb 17, 2022 Overcoming Covid-19 3/30/2022 NEJM, Price AM
Critical illness 96% after 2 doses (Delta†)
79% after 2 doses (Omicron†)
Adolescents (12–18 years)
mRNA 23 states Jul 1, 2021–Feb 17, 2022 Overcoming Covid-19 3/30/2022 NEJM, Price AM
Emergency department/urgent care visits 24% after 1 Janssen dose
54% after 2 Janssen doses
79% after 1 Janssen+1 mRNA dose
83% after 3 mRNA doses
(median interval between receipt of the most recent dose and the ED/UC encounter ranged from 49 to 59 days)
Adults
Janssen, mRNA 10 states Dec 2021–Mar 2022 VISION 3/29/2022 MMWR, Natarajan K
Hospitalization 31% after 1 Janssen dose
67% after 2 Janssen doses
78% after 1 Janssen+1 mRNA dose
90% after 3 mRNA doses
(median interval between receipt of the most recent dose and hospitalization ranged from 48 to 59 days)
Adults
Janssen, mRNA 10 states Dec 2021–Mar 2022 VISION 3/29/2022 MMWR, Natarajan K
Invasive mechanical ventilation (IMV) or death 94% median 60 days after 3 doses (Omicron†)
Adults
mRNA 21 U.S. medical centers Mar 2021–Jan 2022 IVY 3/25/2022 MMWR, Tenforde MW
SARS-CoV-2 infection 31% in children after 2 doses, 14–82 days after 2nd dose (Omicron†)
59% in adolescents after 2 doses (Omicron†)
87% in adolescents after 2 doses, 14–149 days after 2nd dose (Delta†)
Children (5–11 years)
Adolescents (12–15 years)
mRNA 4 states Jul 2021–Feb 2022 PROTECT 3/18/2022 MMWR, Fowlkes AL
Hospitalization 85% after 2 doses (Alpha†)
81% after 2 doses, >150 days before illness onset (Delta†)
88% after 2 doses, 14-150 days (Delta†)
94% after 3 doses (Delta†)
65% after 2 doses (Omicron†)
86% after 3 doses (Omicron†)
Adults
mRNA 21 U.S. hospitals Mar 2021–Jan 2022 IVY 3/9/2022 BMJ, Lauring AS
Emergency department/urgent care visits 46% in children within 14–67 days after dose 2
51% in children within 14–67 days after dose 2 (Omicron†)
83% in adolescents 12–15 years within 14–149 days after dose 2
76% in adolescents 16–17 years within 14–149 days after dose 2
38% in adolescents 12–15 years ≥150 days after dose 2
46% in adolescents 16–17 years ≥150 days after dose 2
86% in adolescents 16–17 years ≥7 days after dose 3
81% in adolescents 16–17 years ≥7 days after dose 3 (Omicron†)
Children (5–11 years)
Adolescents (12–15 years)
Adolescents (16–17 years)
mRNA 10 states Apr 2021–Jan 2022 VISION 3/4/2022 MMWR, Klein NP
Hospitalization 74% in children within 14–67 days after dose 2
92% in adolescents 12–15 years within 14–149 days after dose 2
94% in adolescents 16–17 years within 14–149 days after dose 2
73% in adolescents 12–15 years ≥150 days after dose 2
88% in adolescents 16–17 years ≥150 days after dose 2
Children (5–11 years)
Adolescents (12–15 years)
Adolescents (16–17 years)
mRNA 10 states Apr 2021–Jan 2022 VISION 3/4/2022 MMWR, Klein NP
Hospitalization 37% for primary series alone among immunocompetent adults
65% for primary series plus one booster among immunocompetent adults
76% 7-120 days after receipt of booster dose
63% for primary series plus two boosters among immunocompetent adults
49% for primary series alone among immunocompromised adults
69% for primary series plus one booster among immunocompromised adults
72% 7-120 days after receipt of booster dose
Adults
mRNA, Janssen 21 U.S. Hospitals December 26, 2021-June 30, 2022 IVY 10/11/2022 BMJ Adams, K
Multisystem inflammatory syndrome 84% overall after two doses
78% after two doses among children ages 5-11
90% after two doses among adolescents ages 12-17.
Children (5–11 years)
Adolescents (12–17 years)
mRNA 29 pediatric hospitals across 22 states July 1, 2021- April 7, 2022 Overcoming Covid-19 8/4/2022 CID, Zambrano L
Emergency department/urgent care visits 84% among pregnant adults 14-149 days after 2nd dose, Delta period
75% among pregnant adults ≥150 days after 2nd dose, Delta period
81% among pregnant adults 7-119 days after 3rd dose, Delta period
3% among pregnant adults 14-149 days after 2nd dose, Omicron period
42% among pregnant adults ≥150 days after 2nd dose, Omicron period
79% among pregnant adults 7-119 days after 3rd dose, Omicron period
124% among pregnant adults ≥120 days after 3rd dose, Omicron period
Adults aged 18-45 years
mRNA 10 states June 1, 2021-June 2, 2022 (site-dependent) VISION 9/26/2022 JAMA Open Schrag, S.
Hospitalization 84% among pregnant adults 14-149 days after 2nd dose, Delta period
75% among pregnant adults ≥150 days after 2nd dose, Delta period
81% among pregnant adults 7-119 days after 3rd dose, Delta period
3% among pregnant adults 14-149 days after 2nd dose, Omicron period
42% among pregnant adults ≥150 days after 2nd dose, Omicron period
79% among pregnant adults 7-119 days after 3rd dose, Omicron period
124% among pregnant adults ≥120 days after 3rd dose, Omicron period
99% among pregnant adults, 14-149 days after 2nd dose, Delta period
96% among pregnant adults ≥150 days after 2nd dose, Delta period
97% among pregnant adults 7-119 days after 3rd dose, Delta period
86% among pregnant adults, 14-149 days after 2nd dose, Omicron period
64% among pregnant adults ≥150 days after 2nd dose, Omicron period
86% among pregnant adults, 7-119 days after 3rd dose, Omicron period
53% among pregnant adults ≥120 days after 3rd dose, Omicron period
Adults aged 18-45 years
mRNA 10 states June 1, 2021-June 2, 2022 (site-dependent) VISION 9/26/2022 JAMA Open Schrag, S.
Hospitalization 94% among adults <2months after 2nd dose, pre-Delta period
96% among adults <2 months after 2nd dose, Delta period
87% among adults 4-5 months after 2nd dose, pre-Delta period
89% among adults 4-5 months after 2nd dose, Delta period
73% among adults <2 months after 2nd dose, Omicron period
57% among adults 4-5 months after 2nd dose, Omicron period
96% among adults <2 months after 3rd dose, Delta period
89% among adults <2 months after 3rd dose, Omicron period
66% among adults 4-5 months after 3rd dose, Omicron period
72% among adults ages 50-64 years after 4th dose, Omicron period
76% among adults ages 65 years and older after 4th dose, Omicron period
48% among immunocompromised adults after 4th dose, Omicron period
Adults
mRNA 10 states January 2021-July 12, 2022 VISION 10/03/2022, BMJ, Ferdinands, J
Emergency department/urgent care visits 95% among adults <2 months after 2nd dose, pre-Delta period
93% among adults <2 months after 2nd dose, Delta period
63% among adults <2 months after 2nd dose, Omicron period
96% among adults <2 months after 3rd dose, Delta period
83% among adults <2 months after 3rd dose, Omicron period
46% among adults 4-5 months after 3rd dose, Omicron period
57% among adults ages 50-64 years after 4th dose, Omicron period
73% among adults ages 65 years and older after 4th dose, Omicron period
Adults
mRNA 10 states January 2021-July 12, 2022 VISION 10/03/2022, BMJ, Ferdinands, J
SARS-CoV-2 infection 25.8% against infection among adults <60 days after 2nd vaccine booster dose
Adults
mRNA 19 states March 29–July 25, 2022 N/A 9/30/2022, MMWR, McConeghy, K.
Critical illness 73.9% against critical illness among adults <60 days after 2nd vaccine booster dose
Adults
mRNA 19 states March 29–July 25, 2022 N/A 9/30/2022, MMWR, McConeghy, K
Hospitalization 60.1% against hospitalization among adults <60 days after 2nd vaccine booster dose
Adults
mRNA 19 states March 29–July 25, 2022 N/A 9/30/2022, MMWR, McConeghy, K
Death 89.6% against death among adults <60 days after 2nd vaccine booster dose
Adults
mRNA 19 states March 29–July 25, 2022 N/A 9/30/2022, MMWR, McConeghy, K

#Where applicable, individual vaccine is specified; mRNA refers to COVID-19 vaccines BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) for adults; for children and adolescents, mRNA refers to BNT162b2 (Pfizer-BioNTech); Janssen refers to Ad.26.COV2.S (Johnson & Johnson).
*Confidence interval (CI) for all effectiveness estimates is 95%.
†Dates used for periods of SARS-CoV-2 variant predominance in the United States differ slightly by study and geographic location, but are approximately: Alpha (March 11–July 3, 2021); Delta (Jul 1–Dec 18, 2021); Omicron (Dec 19, 2021–present: sublineages BA.1 [December 2021–March 2022] and BA.2/BA.2.12.1 [March–October 2022]).
How CDC Monitors Vaccine Effectiveness
COVID-19 Vaccines Work

[runrussellrun]

we keep on learning .

Most data that suck find in regards to FDA approval, and FINAL approval, all fall within the timeline of the original mRNA formula to WORK against the variants.

FDA granted FULL approval of phfisters drug/shot....in August of 21.

and yet........science has always know of variants and strains.

If the orgininal formula, followed by bivalents, don't prevent infection........as legally stated in the FDA application......


look.......it's stormy daniels......

nver mind

[runrussellrun]

Same deal. suck'm gonna never post again, IF, you can find "less sick", "less hopital" "won't die" or any other iteration of WHY this covid shot got to FINAL approval.......months deep into any variant or strain. Protip: it's a trap.

Be a hero. Find it. Suck literally thinks it IS the exact same press release from Dec. of 2020

https://www.fda.gov/news-events/press-a ... 19-vaccine

FDA Approves First COVID-19 Vaccine
Approval Signifies Key Achievement for Public Health


For Immediate Release:
August 23, 2021

Today, the U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of COVID-19 disease in individuals 16 years of age and older. The vaccine also continues to be available under emergency use authorization (EUA), including for individuals 12 through 15 years of age and for the administration of a third dose in certain immunocompromised individuals.

“The FDA’s approval of this vaccine is a milestone as we continue to battle the COVID-19 pandemic. While this and other vaccines have met the FDA’s rigorous, scientific standards for emergency use authorization, as the first FDA-approved COVID-19 vaccine, the public can be very confident that this vaccine meets the high standards for safety, effectiveness, and manufacturing quality the FDA requires of an approved product,” said Acting FDA Commissioner Janet Woodcock, M.D. “While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated. Today’s milestone puts us one step closer to altering the course of this pandemic in the U.S.”

Since Dec. 11, 2020, the Pfizer-BioNTech COVID-19 Vaccine has been available under EUA in individuals 16 years of age and older, and the authorization was expanded to include those 12 through 15 years of age on May 10, 2021. EUAs can be used by the FDA during public health emergencies to provide access to medical products that may be effective in preventing, diagnosing, or treating a disease, provided that the FDA determines that the known and potential benefits of a product, when used to prevent, diagnose, or treat the disease, outweigh the known and potential risks of the product.

FDA-approved vaccines undergo the agency’s standard process for reviewing the quality, safety and effectiveness of medical products. For all vaccines, the FDA evaluates data and information included in the manufacturer’s submission of a biologics license application (BLA). A BLA is a comprehensive document that is submitted to the agency providing very specific requirements. For Comirnaty, the BLA builds on the extensive data and information previously submitted that supported the EUA, such as preclinical and clinical data and information, as well as details of the manufacturing process, vaccine testing results to ensure vaccine quality, and inspections of the sites where the vaccine is made. The agency conducts its own analyses of the information in the BLA to make sure the vaccine is safe and effective and meets the FDA’s standards for approval.

Comirnaty contains messenger RNA (mRNA), a kind of genetic material. The mRNA is used by the body to make a mimic of one of the proteins in the virus that causes COVID-19. The result of a person receiving this vaccine is that their immune system will ultimately react defensively to the virus that causes COVID-19. The mRNA in Comirnaty is only present in the body for a short time and is not incorporated into - nor does it alter - an individual’s genetic material. Comirnaty has the same formulation as the EUA vaccine and is administered as a series of two doses, three weeks apart.

“Our scientific and medical experts conducted an incredibly thorough and thoughtful evaluation of this vaccine. We evaluated scientific data and information included in hundreds of thousands of pages, conducted our own analyses of Comirnaty’s safety and effectiveness, and performed a detailed assessment of the manufacturing processes, including inspections of the manufacturing facilities,” said Peter Marks, M.D., Ph.D., director of FDA’s Center for Biologics Evaluation and Research. “We have not lost sight that the COVID-19 public health crisis continues in the U.S. and that the public is counting on safe and effective vaccines. The public and medical community can be confident that although we approved this vaccine expeditiously, it was fully in keeping with our existing high standards for vaccines in the U.S."

FDA Evaluation of Safety and Effectiveness Data for Approval for 16 Years of Age and Older
The first EUA, issued Dec. 11, for the Pfizer-BioNTech COVID-19 Vaccine for individuals 16 years of age and older was based on safety and effectiveness data from a randomized, controlled, blinded ongoing clinical trial of thousands of individuals.

To support the FDA’s approval decision today, the FDA reviewed updated data from the clinical trial which supported the EUA and included a longer duration of follow-up in a larger clinical trial population.

Specifically, in the FDA’s review for approval, the agency analyzed effectiveness data from approximately 20,000 vaccine and 20,000 placebo recipients ages 16 and older who did not have evidence of the COVID-19 virus infection within a week of receiving the second dose. The safety of Comirnaty was evaluated in approximately 22,000 people who received the vaccine and 22,000 people who received a placebo 16 years of age and older.

Based on results from the clinical trial, the vaccine was 91% effective in preventing COVID-19 disease.

More than half of the clinical trial participants were followed for safety outcomes for at least four months after the second dose. Overall, approximately 12,000 recipients have been followed for at least 6 months.

The most commonly reported side effects by those clinical trial participants who received Comirnaty were pain, redness and swelling at the injection site, fatigue, headache, muscle or joint pain, chills, and fever. The vaccine is effective in preventing COVID-19 and potentially serious outcomes including hospitalization and death.

Additionally, the FDA conducted a rigorous evaluation of the post-authorization safety surveillance data pertaining to myocarditis and pericarditis following administration of the Pfizer-BioNTech COVID-19 Vaccine and has determined that the data demonstrate increased risks, particularly within the seven days following the second dose. The observed risk is higher among males under 40 years of age compared to females and older males. The observed risk is highest in males 12 through 17 years of age. Available data from short-term follow-up suggest that most individuals have had resolution of symptoms. However, some individuals required intensive care support. Information is not yet available about potential long-term health outcomes. The Comirnaty Prescribing Information includes a warning about these risks.

Ongoing Safety Monitoring
The FDA and Centers for Disease Control and Prevention have monitoring systems in place to ensure that any safety concerns continue to be identified and evaluated in a timely manner. In addition, the FDA is requiring the company to conduct postmarketing studies to further assess the risks of myocarditis and pericarditis following vaccination with Comirnaty. These studies will include an evaluation of long-term outcomes among individuals who develop myocarditis following vaccination with Comirnaty. In addition, although not FDA requirements, the company has committed to additional post-marketing safety studies, including conducting a pregnancy registry study to evaluate pregnancy and infant outcomes after receipt of Comirnaty during pregnancy.

The FDA granted this application Priority Review. The approval was granted to BioNTech Manufacturing GmbH.

Related Information
Comirnaty Prescribing Information
Cormirnaty and Pfizer-BioNTech COVID-19 Vaccine | FDA

[runrussellrun]

The Countermeasures Injury Compensation
Program (CICP)
To encourage expeditious development and deployment of medical countermeasures during a
public health emergency, the PREP Act authorizes the Secretary of HHS (the Secretary) to limit
legal liability for losses resulting from the administration of medical countermeasures such as
diagnostics, treatments, and vaccines.19 In a declaration effective February 4, 2020 (the PREP Act
Declaration), the Secretary invoked the PREP Act and declared the spread of COVID-19 to be a
public health emergency warranting liability protections for covered countermeasures (e.g., drugs,
biologics, and medical devices used to diagnose, treat, or prevent COVID-19).
20 Pursuant to the
PREP Act Declaration and its subsequent amendments,21 manufacturers, distributors, and health
care providers are generally immune from legal liability (i.e., they cannot be sued for money
damages in court) for losses related to the administration or use of covered countermeasures
against COVID-19.22
In addition to providing immunity from liability, the PREP Act established CICP, a compensation
program for individuals seriously injured or killed as a direct result of the administration or use of
a covered countermeasure.23 CICP is a regulatory process administered by the Health Resources
and Services Administration (HRSA).24 HRSA regulations govern CICP’s procedures and
eligibility determinations.25

https://crsreports.congress.gov/product/pdf/R/R46982